Retrophin (now Travere Therapeutics)

The clinical trials section below shows all active and recruiting studies sponsored by Retrophin (now Travere Therapeutics), sourced live from ClinicalTrials.gov. Each trial includes its current recruitment status, study phase (Phase 1 through Phase 4), conditions under investigation, and the number of active trial sites. The FDA-approved drugs section lists treatments that have received U.S. Food and Drug Administration approval, with brand names, generic names, approval dates, and matched rare disease indications from the openFDA database.

Retrophin (now Travere Therapeutics) is headquartered in San Diego, United States, founded in 2011, publicly traded under the ticker symbol TVTX. The company dedicates its research and development resources exclusively to rare and orphan diseases, working to bring innovative treatments to patients with conditions that have historically had limited or no treatment options.